ecopipam has been researched along with Basal Ganglia Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cools, AR; Ellenbroek, BA; Prinssen, EP; Stamatovic, B | 1 |
| Coffin, V; McHugh, D | 1 |
2 other study(ies) available for ecopipam and Basal Ganglia Diseases
| Article | Year |
|---|---|
The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Dopamine D2 Receptor Antagonists; Drug Interactions; Forelimb; Haloperidol; Hindlimb; Male; Raclopride; Rats; Rats, Wistar; Reaction Time; Receptors, Dopamine D1; Salicylamides | 1993 |
The reversal of extrapyramidal side effects with SCH 39166, a dopamine D1 receptor antagonist.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzazepines; Cebus; Dopamine Antagonists; Female; Haloperidol; Receptors, Dopamine D1 | 1991 |